Next Article in Journal
Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity
Next Article in Special Issue
Role of microRNAs as Clinical Cancer Biomarkers for Ovarian Cancer: A Short Overview
Previous Article in Journal
Sterculic Acid: The Mechanisms of Action beyond Stearoyl-CoA Desaturase Inhibition and Therapeutic Opportunities in Human Diseases
Previous Article in Special Issue
Identification and Validation Model for Informative Liquid Biopsy-Based microRNA Biomarkers: Insights from Germ Cell Tumor In Vitro, In Vivo and Patient-Derived Data
Open AccessArticle

Investigating the Potential and Pitfalls of EV-Encapsulated MicroRNAs as Circulating Biomarkers of Breast Cancer

1
Discipline of Surgery, Lambe Institute for Translational Research, School of Medicine, National University of Ireland Galway, Galway, H91 YR71, Ireland
2
Laboratory for Biological Characterisation of Advanced Materials (LBCAM) and Advanced Materials and Bioengineering Research (AMBER) Centre, Trinity Translational Medicine Institute, Trinity College Dublin, James Street, Dublin, D08 W9RT, Ireland
3
School of Mathematics, Statistics and Applied Mathematics, National University of Ireland Galway, Galway, H91 YR71, Ireland
4
Centre for Microscopy and Imaging, Discipline of Anatomy, School of Medicine, National University of Ireland Galway, Galway, H91 YR71, Ireland
5
Regenerative Medicine Institute, School of Medicine, College of Medicine, Nursing and Health Sciences, National University of Ireland Galway, Galway, H91 YR71, Ireland
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Cells 2020, 9(1), 141; https://doi.org/10.3390/cells9010141
Received: 3 December 2019 / Revised: 20 December 2019 / Accepted: 27 December 2019 / Published: 7 January 2020
(This article belongs to the Special Issue microRNA as Biomarker)
Extracellular vesicles (EVs) shuttle microRNA (miRNA) throughout the circulation and are believed to represent a fingerprint of the releasing cell. We isolated and characterized serum EVs of breast tumour-bearing animals, breast cancer (BC) patients, and healthy controls. EVs were characterized using transmission electron microscopy (TEM), protein quantification, western blotting, and nanoparticle tracking analysis (NTA). Absolute quantitative (AQ)-PCR was employed to analyse EV-miR-451a expression. Isolated EVs had the appropriate morphology and size. Patient sera contained significantly more EVs than did healthy controls. In tumour-bearing animals, a correlation between serum EV number and tumour burden was observed. There was no significant relationship between EV protein yield and EV quantity determined by NTA, highlighting the requirement for direct quantification. Using AQ-PCR to relate miRNA copy number to EV yield, a significant increase in miRNA-451a copies/EV was detected in BC patient sera, suggesting potential as a novel biomarker of breast cancer.
Keywords: breast cancer; extracellular vesicles; exosomes; microRNA; biomarker; EV characterization breast cancer; extracellular vesicles; exosomes; microRNA; biomarker; EV characterization
MDPI and ACS Style

Moloney, B.M.; Gilligan, K.E.; Joyce, D.P.; O’Neill, C.P.; O’Brien, K.P.; Khan, S.; Glynn, C.L.; Waldron, R.M.; Maguire, C.M.; Holian, E.; Naughton, E.; Elhadi, M.; Grealish, A.B.; Malone, C.; McDermott, E.; Dockery, P.; Ritter, T.; Prina-Mello, A.; Kerin, M.J.; Dwyer, R.M. Investigating the Potential and Pitfalls of EV-Encapsulated MicroRNAs as Circulating Biomarkers of Breast Cancer. Cells 2020, 9, 141.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop